Following adjustment for baseline differences, there was an apparent treatment-related decrease in IL-6 concentrations in GSK2586881-treated patients compared with placebo after 24 h that did not reach statistical significance (posterior probability distribution of 0.5130–0.9254).
← all excerpts
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.
1
—
—